ReviewAIDS (London, England)2025
Could reduced dosing maintain more people on antiretrovirals after the sudden cuts in USAID funding? A crisis response.
Review in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Understanding Adolescent Anti-Retroviral Therapy Use in the BREATHER-Plus Trial: Qualitative Findings From South Africa and Uganda.Journal of the International AIDS Society · 2026Trial
- Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure.PLoS pathogens · 2026Article
- Overcoming barriers, driving progress: Clinical science at IAS 2025.Journal of the International AIDS Society · 2026Article
- A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens.The Journal of antimicrobial chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiretroviral therapy shortages caused by sudden and severe cuts in USAID and PEPFAR have focused attention on strategies to extend antiretroviral supplies and mitigate this crisis. Efficacy data are now available from seven randomized controlled intermittent triple antiretroviral therapy trials. For countries with urgent drug shortages, this evidence supports intermittent dosing 4-5 days-per-week to extend antiretroviral supplies, with clinical benefits for people living with HIV and continued population benefits of minimizing HIV transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.